Pharma companies are set to post resilient growth in their Q2 earnings for the financial year 2026-27, despite facing pricing pressures in the US generics market and higher logistical costs. This growth is mainly driven by strong domestic healthcare demand and expansion in contract development and manufacturing organisations (CDMOs).
- Domestic healthcare demand supports pharma sector growth.
- US export business faces decline due to pricing pressures and lower sales.
- CDMO segment growth strengthens manufacturing capabilities.
- US exempts certain specialty drugs from import duties, benefiting Indian drugmakers.
- Currency depreciation supports revenue growth for pharma exporters.
Why are pharma companies expected to grow despite US market challenges?
Pharma companies like Dr Reddy’s, Torrent Pharma, and Zydus Life are benefiting from increased demand in the domestic Indian market. While exports to the US are expected to decline by about 15% year-on-year due to pricing pressures and lower sales, growth in domestic formulations and new product launches are helping offset these challenges. Additionally, the CDMO segment is expanding as global pharmaceutical companies outsource manufacturing and development to Indian firms.
How does the US import duty exemption impact Indian pharma companies?
The United States has exempted certain specialty drugs imported from 20 countries, including India, from its 100% import duty. This exemption provides significant relief to eligible Indian drugmakers by eliminating import duties on specialty medicines, which can improve their competitiveness in the US market, the largest export destination for Indian pharmaceutical companies.
What role does the Indian rupee’s value play in pharma earnings?
The Indian rupee has depreciated by around 6% against the US dollar this year. A weaker rupee benefits Indian pharma exporters by increasing the value of their dollar-denominated revenues when converted back to rupees. This currency effect is expected to support overall revenue growth for pharma companies in the Q2 period.
What challenges do pharma companies face in the near term?
Despite growth prospects, pharma companies face near-term challenges such as pricing pressure in the US generics market, elevated input and logistics costs due to geopolitical conflicts, and increased regulatory scrutiny. These factors may lead to margin contractions for companies like Cipla, Dr Reddy’s, and Zydus Life, although Torrent Pharma may see margin improvements.
What should investors focus on in upcoming Q2 earnings reports?
Investors are advised to look beyond revenue growth and examine the quality and sustainability of business performance. Key indicators include domestic formulation growth, new product pipelines, contributions from complex generics and specialty products, and the pace of recovery in the US market. Additionally, order inflows, customer additions, capacity utilization, and the conversion of development projects into commercial manufacturing are important factors to watch.
What is the long-term outlook for the Indian pharma sector?
Experts see a large opportunity for Indian pharma companies to expand capabilities in complex generics, specialty medicines, and CDMOs. As global pharmaceutical companies diversify supply chains, Indian firms are well positioned to benefit by strengthening manufacturing, research, and compliance capabilities. Companies that move up the value chain and build strong relationships with global innovators may capture significant long-term growth opportunities.
